Abstract library

203 results for "van den Heuvel".
#78 The diagnostic and prognostic value of elevated proGRP levels in well- and moderately differentiated neuroendocrine tumors
Introduction: Chromogranin A (CgA) is the most frequently used marker in well- (grade 1) and moderately (grade 2) differentiated NETs. Although CgA is a more sensitive marker than the 5-HIAA, which was widely used until the last decade, CgA has some limitations. False-positively elevated CgA may occur in renal impairment, atrophic gastritis and during treatment of proton-pump inhibitors. Progastrin-releasing peptide (proGRP) was recently reported as a promising tumor marker for small cell lung cancer. Limited data suggests that ProGRP may be a potential tumor marker in NE tumors.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Msc Catharina M Korse
#2181 Using Adult Stem-Cell Derived Organoids to Model Neuroendocrine Tumor Growth
Introduction: Neuroendocrine tumors (NETs) are a genetically diverse set of rare tumors, which have limited treatment options. The development of more effective therapies for NETs has been limited in part by the absence of in vitro and in vivo models that accurately represent the heterogeneity of these tumors.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: PhD Talya Dayton
#653 Interobserver Variability of Pulmonary Carcinoids
Introduction: Lung carcinoids are neuroendocrine tumors histopathologically classified into typical (TC; no necrosis, <2 mitoses/2 mm2) and atypical (AC; necrosis or 2-10 mitoses/2 mm2). Identification of mitoses may be hampered by the presence of apoptotic cells, and reported prediction of prognosis based on histopathology varies, especially for ACs.
Conference: 10th Annual ENETS Conference (2013)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: MSc Dorian Swarts
#1778 Chemotherapy for Pulmonary Large Cell Neuroendocrine Carcinomas: Does the Regimen Matter?
Introduction: Metastatic pulmonary large cell neuroendocrine carcinoma (LCNEC) is a rare disease and the most effective chemotherapy regimen is debated, i.e. small cell lung carcinoma (SCLC) or non-small cell lung carcinoma (NSCLC) chemotherapy.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment – Chemotherapy, medical treatment - others
Presenting Author: Jules Derks
Keywords: lcnec, chemotherapy, nec, lung
#1418 Extra-Pulmonary Neuroendocrine Carcinomas: A National Population Based Study
Introduction: Extra pulmonary neuroendocrine carcinomas(EPNEC) are rare tumours, this implies lack of knowledge on the burden.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MSc. Jan Maarten Van Der Zwan
Keywords: EP-NEC
#1184 A National Pathology Registration Analysis of Applied Terminology in Pulmonary Neuroendocrine Tumors/Carcinomas: Is the WHO 2004 Classification in Line with Clinical Practice?
Introduction: Nomenclature of the WHO 2004 should be used for pulmonary neuro-endocrine tumors (NET) and carcinomas (NEC) classification.
Conference: 12th Annual ENETS Conference (2015)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: MD Jules Derks
Keywords: NET, Diagnosis
#1231 Neuroendocrine Tumor (NET) Patient (pt) Experience and Disease Burden: Results from the First Global NET Pt Survey - A Collaboration Between the International Neuroendocrine Cancer Alliance (INCA) and Novartis Pharmaceuticals
Introduction: Global data on impact of NETs on pts’ lives, including differences by disease location, are poorly described. We present global data on pt experience and disease burden by NET type.
Conference: 12th Annual ENETS Conference (2015)
Category: ...none of the below
Presenting Author: Professor Philippe Ruszniewski
Keywords: Symptom burden
#1167 Cowden Syndrome and Concomitant Pulmonary Neuroendocrine Tumor: A Presentation of Two Cases
Introduction: Cowden Syndrome is a multiorgan disorder with germline mutations in the tumor suppressor gene PTEN leading to dysfunctional cell growth and risk of neoplasms in e.g. breast and thyroid, but no association with NET has been described.
Conference: 12th Annual ENETS Conference (2015)
Category: Clinical cases/reports
Presenting Author: Lene Ringholm
#109 Transarterial chemoebolization (TACE) of liver metastases derived from neuroendocrine tumors is an effective treatment only in patients with low or mediate hepatic tumor burden
Introduction: The onset of metastases in patients with neuroendocrine tumors of the gastrointestinal tract (GEP-NET) represents a negative predictor of survival and tumor-associated complications. Thereby, most of these patients develop liver metastases during their disease. Transarterial chemoembolization (TACE) has been shown before to be an effective and safe treatment of liver metastases. However, the optimal time point in treatment of liver metastases has not yet been determined, especially in patients with non-functional GEP-NET.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Anja Rinke
Authors: Rinke A, König A, Müller D, König U, ...
#1276 Caregivers’ Burden of Patients with Neuroendocrine Tumor and Related Factors
Introduction: Rare and increasing rapidly,patients with NETs have got more and more attention.With so many unknown and the long course of the disease, the caregaviers should bear a long and huge burden.However, the relative reviews are rare.
Conference: 13th Annual ENETS conference (2016)
Category: ...none of the above
Presenting Author: Liyan Zhang
Authors: Zhang L, ...
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.